Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

23 jun 2013 8:30 a.m. - 27 jun 2013 12:45 p.m.

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

Session Chair(s)

Jayanthi  Reddy, MBA, MS

Jayanthi Reddy, MBA, MS

Director, Global Project Management

Merck & Co., Inc., United States

Learning Objective : Describe how companies address strategic choices when evaluating new business models, using the advent of biosimilar development as a case study; Discuss different strategic approaches to biosimilar development.

Speaker(s)

Steve  Farrand, PHD, MSC

CMC Challenges to Biosimilar Development

Steve Farrand, PHD, MSC

Merck Research Laboratories, United States

Vice President BioProcess Development

Andrew  Rankin, PHD

Clinical Challenges and Strategic Approaches to Biosimilar Development

Andrew Rankin, PHD

Pharnaceutical Consultant, United States

Pharmaceutical Consultant

Qinghai  Zhao

Nonclinical Challenges to Biosimilar Development

Qinghai Zhao

Teva BioPharmaceuticals USA, United States

Director, Protein Sciences

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.